Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Methylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL4335369 | 1.00 | — | — | |
| Methylamine SCHEMBL5492498 | 0.89 | — | — | |
| Methylamine SCHEMBL3240364 | 0.89 | — | — | |
| Methylamine SCHEMBL8507247 | 0.89 | — | — | |
| Methylamine SCHEMBL8644698 | 0.89 | — | — | |
| Methylamine SCHEMBL6130807 | 0.89 | — | — | |
| Methylamine SCHEMBL9853401 | 0.89 | — | — | |
| Methylamine SCHEMBL8931568 | 0.89 | — | — | |
| Methylamine SCHEMBL538799 | 0.89 | — | — | |
| Methylamine SCHEMBL2341548 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031132-B2 | Systems and methods for the treatment of hemoglobinopathies | EDITAS MEDICINE, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4392076-A1 | SIRP-ALPHA ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4388103-A1 | NECTIN-4 ANTIBODIES AND CONJUGATES | Tallac Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118215485-A | Branched trisaccharide modified nucleic acid compounds | 诺华股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118215484-A | Staggered trisaccharide modified nucleic acid compounds | 诺华股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240191197-A1 | MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240191242-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2024105654-A1 | METHODS AND COMPOSITIONS INCLUDING CONJUGATED DNAZYMES | 1E THERAPEUTICS, LTD. (IL) | 2024-05-23 | — | — | WO | disclosed |
| EP-3583211-B1 | METHOD FOR THE SYNTHESIS OF DNA CONJUGATES BY MICELLAR CATALYSIS | UNIV DORTMUND TECH (DE) | 2024-04-10 | — | — | EP | disclosed |
| US-11920136-B2 | Transglutaminase-mediated conjugation | Tallac Therapeutics, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2000071559-A9 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | INVITROGEN CORP (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1091972-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000071559-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | INVITROGEN CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6043353-A | FOR SOLID PHASE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL, INC. (CA) | 2000-03-28 | — | — | US | disclosed |
| WO-2000001711-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2000-01-13 | — | — | WO | disclosed |
| EP-0876390-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1998-11-11 | — | — | EP | disclosed |
| EP-0866072-A1 | Processes for purifying synthetic oligonucleotides | Beckman Coulter, Inc. (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5770723-A | HIGH SPEED DEPROTECTION AND CLEAVAGE WITH METHYLAMINE; ADDINGSODIUM CHLORIDE AND/OR AMMONIUM ACETATE | BECKMAN INSTRUMENTS, INC. | 1998-06-23 | — | — | US | disclosed |
| WO-1997023496-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
| US-5601979-A | SOLID PHASE DNA SYNTHESIS | CPG, INC. (US) | 1997-02-11 | — | — | US | disclosed |